The Tumor Stroma as Mediator of Drug Resistance - A Potential Target to Improve Cancer Therapy?

Current Pharmaceutical Biotechnology

Volumn 13, Issue 11, 2012, Pages 2259-2272

  Sebens, Susanne ^a   Schäfer, Heiner ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Apoptosis; Chemoresistance; Desmoplasia; Extracellular matrix; Microenvironment; Molecular targets

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CANAKINUMAB; CHEMOKINE RECEPTOR CXCR4; CILENGITIDE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETARACIZUMAB; FAS LIGAND; HERMES ANTIGEN; INTEGRIN; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; N ACETYLPROLYLHISTIDYLSERYLCYSTEINYLASPARAGINE AMIDE; NERVE CELL ADHESION MOLECULE L1; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PLERIXAFOR; PROTEIN BAX; PROTEIN BCL 2; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; SCLEROPROTEIN; T 140; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VINCRISTINE; VITRONECTIN; VOLOCIXIMAB;

ARTICLE; BREAST CARCINOMA; CANCER STEM CELL; CARCINOGENESIS; CELL CYCLE ARREST; CHEMOTHERAPY; COLON CANCER; GLIOBLASTOMA; HUMAN; LUNG NON SMALL CELL CANCER; NEOPLASM; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; SOLID TUMOR; STROMA; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ANIMALS; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 84873451435     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112802501999     Document Type: Article

References (167)

1. Bissell, M.J.; Radisky, D. Putting tumours into context. Nat. Rev. Cancer, 2001, 1(1), 46-54.
2. Konopleva, M.; Tabe, Y.; Zeng, Z.; Andreeff, M. Therapeutic targeting of micro-environmental interactions in leukemia: Mechanisms and approaches. Drug Resist. Updat, 2009, 12(4-5), 103-113.
3. Lane S.W.; Scadden D.T.; Gilliland D.G. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood, 2009, 114(6), 1150-1157.
4. Tlsty, T.D.; Coussens, L.M. Tumor stroma and regulation of cancer development. Annu. Rev. Pathol. Mech. Dis., 2006, 1, 119-150.
5. Whiteside, T.L. The tumor microenvironment and its role in promoting tumor growth. Oncogene, 2008, 27(45), 5904-5912.
6. Kleeff, J.; Beckhove, P.; Esposito I.; Herzig, S.; Huber, P.E.; Löhr, J.M.; Friess, H. Pancreatic cancer microenvironment. Int. J. Cancer, 2007, 121(4), 699-705.
7. Micke, P.; Östmann, A. Tumour-stroma interaction: cancerassociated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer, 2004, 45(Suppl.2), S163-S175.
8. Hofmeister, V.; Schrama, D.; Becker, J.C. Anti-cancer therapies targeting the tumor stroma. Cancer Immunol. Immunother., 2008, 57(1), 1-17.
9. Chu, G.C.; Kimmelmann, A.C.; Hezel, A.F.; DePinho, R.A. Stromal biology of pancreatic cancer. J. Cell Biochem., 2007, 101(4), 887-907.
10. Mahadevan, D.; von Hoff, D.D. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol. Cancer Ther., 2007, 6(4), 1186-1197.
11. Sethi, T.; Rintoul, R.C.; Moore, S.M.; MacKinnon, A.C.; Salter, D.; Choo, C.; Chilvers, E.R.; Dransfield, I.; Donnelly, S.C.; Strieter, R.; Haslett, C. Extracellular matrix proteins protect small cell lung cancer cells agains apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med., 1999, 5(6), 662-668.
12. Kerbel, R.S.; St. Croix, B.; Florenes, V.A.; Rak, J. Induction and reversal of cell adhesion-dependent multicellular drug resistance in solid breast tumors. Hum Cell, 1996, 9(4), 257-264.
13. Spottl, T.; Hausmann, M.; Gunckel, M.; Herfarth, H.; Herlyn, M.; Schoelmerich, J.; Rogler, G. A new organotypic model to study cell interactions in the intestinal mucosa. Eur. J. Gastro. Hepatol., 2006, 18(8), 901-909.
14. Fujita, H.; Ohuchida, K.; Mizumoto, K.; Egami, T.; Miyoshi, K.; Moriyama, T.; Cui, L.; Yu, J.; Zhao, M.; Manabe, T.; Tanaka, M. Tumor-stromal interactions with direct cell contacts enhance proliferation of human pancreatic carcinoma cells. Cancer Sci., 2009, 100(12), 2309-2317.
15. Müerköster, S.; Wegehenkel, K.; Arlt, A.; Witt, M.; Sipos, B.; Kruse, M.-L.; Sebens, T.; Klöppel, G.; Kalthoff, H.; Fölsch, U.R.; Schäfer, H. Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res., 2004, 64(4), 1331-1337.
16. Chometon, G.; Jendrossek, V. Targeting the tumour stroma to increase efficacy of chemo-and radiotherapy. Clin. Transl. Oncol., 2009, 11(2), 75-81.
17. Westhoff, M.-A.; Fulda, S. Adhesion-mediated apoptosis resistance in cancer. Drug Resist. Updat, 2009, 12(4-5), 127-136.
18. Meads, M.B.; Gatenby, R.A., Dalton, W.S. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat. Rev. Cancer, 2009, 9(9), 665-674.
19. Farmer, P.; Bonnefoi, H.; Anderle, P.; Cameron, D.; Wirapati, P.; Becette, V., André, S., Piccart, M.; Campone, M.; Brain, E.; MacGrogan, G.; Petit, T., Jassem, J.; Bibeau, F.; Blot, E.; Bogaerts, J.; Aguet, M.; Bergh, J.; Iggo, R.; Delorenzi M. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat. Med., 2009, 15(1), 68-74.
20. Whiteside, T.L. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Sem. Cancer Biol., 2006, 16(1), 3-15.
21. Mantovani, A.; Allavena, P.; Sica, A.; Balkwill F. Cancer-related inflammation. Nature, 2008, 254(7203), 436-444.
22. Guo, W.; Giancotti, F.G. Integrin signaling during tumour progression. Nat. Rev. Mol. Cell. Biol., 2004, 6(5), 816-826.
23. Gatenby, R.A.; Gillies, R.J. A microenvironmental model of carcinogenesis. Nat. Rev. Cancer, 2008, 8(1), 56-61.
24. Kerr, J.F.; Wyllie, A.H.; Currie, A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer, 1972, 26(4), 239-257.
25. Hengartner, M.O. The biochemistry of apoptosis. Nature, 2000, 407(6805), 770-776.
26. Chowdhury, I.; Tharakan, B.; Bhat, G.K. Current concepts in apoptosis: the physiological suicide program revisited. Cell. Mol. Biol. Lett., 2006, 11(4), 506-525.
27. Pop, C.; Salvesen, G.S. Human caspases: activation, specificity, and regulation. J. Biol. Chem., 2009, 284(33), 21777-21781.
28. Barnhart, B.C.; Lee, J.C.; Alappat, E.C.; Peter, M.E. The death effector domain protein family. Oncogene, 2003, 22(53), 8634-8644.
29. Adams, J.M.; Cory, S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene, 2007, 26(9), 1324-1337.
30. Ow, Y.P.; Green, D.R.; Hao, Z.; Mak, T.W. Cytochrome c: functions beyond respiration. Nat. Rev. Mol. Cell. Biol., 2008, 9(7), 532-542.
31. Earnshaw, W.C.; Martins, L.M.; Kaufmann, S.H. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu. Rev. Biochem., 1999, 68, 383-424.
32. Fulda, S.; Debatin, K.-M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene, 2006, 25(34), 4798-4811.
33. Chaigne-Delalande, B.; Moreau, J.F.; Legembre, P. Rewinding the DISC. Arch. Immunol. Ther. Exp. (Warsz), 2008, 56(1), 9-14.
34. Wei, Y.; Fan, T.; Yu, M. Inhibitor of apoptosis proteins and apoptosis. Acta Biochim. Biophys. Sin., 2008, 40(4), 278-288.
35. Shain, K.H.; Dalton, W.S. Cell adhesion is a key determinant in de Novo multidrug resistance (MDR): New targets for the prevention of acquired MDR. Mol. Cancer Ther., 2001, 1(1), 69-78.
36. DeClerck, Y.A.; Mercurio, A.M.; Stack, M.S.; Chapman, H.A.; Zutter, M.M.; Muschel, R.J.; Raz, A.; Matrisian, L.M.; Sloane, B.F.; Noel, A.; Hendrix, M.J.; Coussens, L.; Padarathsingh, M. Proteases, extracellular matric, and cancer. Am. J. Pathol., 2004, 164(4), 1131-1139.
37. Micke, P.; Östmann, A. Tumour-stroma interaction: cancerassociated fibroblasts as novel targets in anti-cancer therapy. Lung Cancer, 2004, 45 (Suppl 2), S163-S175.
38. Liotta, L.A.; Kohn, E.C. The microenvironment of the tumour-host interface. Nature, 2001, 411(6835), 375-379.
39. Ramos, J.W. The regulation of the extracellular signal-regulated kinase (ERK) in mammalian cells. Int. J. Biochem. Cell Biol., 2008, 40(12), 2707-2719.
40. Barberis, L.; Wary, K.K.; Fiucci, G.; Liu, F.; Hirsch, E.; Brancaccio, M.; Altruda, F.; Tarone, G.; Giancotti, F.G. Distinct roles of the adaptor protein Shc and focal adhesion kinase in integrin signalling to ERK. J. Biol. Chem., 2000, 275(47), 36532-36540.
41. Schlaepfer, D.D.; Hanks, S.K.; Hunter, T., van der Geer, P. Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase. Nature, 1994, 372(6508), 786-791.
42. Peyssonaux, C.; Eychene, A. The Raf/MEK/ERK pathway: new concepts of activation. Biol. Cell, 2001, 93(1-2), 53-62.
43. Yan, L.; Lavin, V.A.; Moser, L.R.; Cui, Q.; Kanies, C.; Yang, E. PP2A regulates the pro-apoptotic activity of FOXO1. J. Biol. Chem., 2008, 283(12), 7411-7420.
44. Ley, R.; Ewings, K.E.; Hadfield, K.; Howes, E.; Balmanno, K.; Cook, S.J. Extracellular signal-regulated kinases 1/2 are serumstimulated "Bim(EL) kinases" that bind to the BH3-only protein BIM(EL) causing its phosphorylation and turnover. J. Biol. Chem., 2004, 279(10), 8837-8847.
45. Boucher, M.J.; Morisset, J.; Vachon, P.H.; Reed, J.C.; Laine, J.; Rivard, N. MEK/ERK signalling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J. Cell. Biochem., 2000, 79(3), 355-369.
46. Guan, J.L. Focal adhesion kinase in integrin signalling. Matrix Biol., 1997, 16(4), 195-200.
47. Nicholson, K.M.; Anderson, N.G. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal., 2002, 14(5), 381-395.
48. Manning, B.D., Cantley, L.C. AKT/PKB signalling: navigating downstream. Cell, 2007, 129(7), 1261-1274.
49. Westhoff, M.A.; Kandenwein, J.A.; Karl, S.; Vellanki, S.H.K.; Braun, V.; Eramo, A.; Antoniadis, G.; Fulda, S. The pyridinylfuranopyrimidine inhibitor PI-103 chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair. Oncogene, 2009, 28(40), 3586-3596.
50. Arlt, A.; Gehrz, A.; Müerköster, S.; Vorndamm, J.; Kruse, M.-L.; Fölsch, U.R.; Schäfer, H. Role of NF-kB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabineinduced cell death. Oncogene, 2003, 22(21), 3243-3251.
51. Karin, M. Nuclear factor-kB in cancer development and progression. Nature, 2006, 441(7092), 431-436.
52. Kim, H.J.; Hawke, N.; Baldwin, A.S. NF-KB and IKK as therapeutic targets in cancer. Cell Death Diff., 2006, 13(5), 738-747.
53. Karin, M.; Yamamoto, Y.; Wang, Q.M. The IKK NF-kB system: A treasure trove for drug development. Nat. Rev., 2004, 3(1), 17-26.
54. Hynes, R.O. Integrins: bidirectional, allosteric signalling machines. Cell, 2002, 110(6), 673-687.
55. Stupack, D.G. Integrins as a distinct subtype of dependence receptors. Cell Death Differ., 2005, 12(8), 1021-1030.
56. Jin, H.; Varner, J. Integrins: roles in cancer development and as treatment targets. Br. J. Cancer, 2004, 90(3), 561-565.
57. Alphonso, A.; Alahari, S.K. Stromal cells and integrins: Conforming to the needs of the tumor microenvironment. Neoplasia, 2009, 11(12), 1264-1271.
58. Fridman, R.; Giaccone, G.; Kanemoto, T.; Martin, G.R.; Gazdar, A.F.; Mulshine, J.L. Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proc. Natl. Acad. Sci. USA, 1990, 87(17), 6698-6702.
59. Rintoul, R.C., Sethi, T. Extracellular matrix regulation of drug resistance in small-cell lung cancer. Clin. Sci., 2002, 102(4), 417-424.
60. Hodkinson, P.S.; Elliott, T.; Wong, W.S.; Rintoul, R.C.; Mackinnon, A.C.; Haslett, C.; Sethi, T. ECM overrides DNA damageinduced cell cycle arrest and apoptosis in small-cell lung cancer cells through ß1 integrin-dependent activation of PI3-kinase. Cell Death Diff., 2006, 13(10), 1776-1788.
61. Chrenek, M.A.; Wong, P.; Weaver, V.M. Tumour-stromal interactions. Integrins and cell adhesions as modulators of mammary cell survival and transformation. Breast Cancer Res., 2001, 3(4), 224-229.
62. Gilmore, A.P.; Metcalfe, A.D., Romer, L.H.; Streuli, C.H. Integrinmediated survival signals regulate the apoptotic function of Bax through its conformation and subcellular localization. J. Cell Biol., 2000, 149(2), 431-446.
63. Nista, A.; Leonetti, C.; Mattioni, M.; Santoni, A. Functional role of alpha4beta1 and alpha5beta1 integrin fibronectin receptors expressed on adriamycin-resistant MCF-7 human mammaray carcinoma cells. Int. J. Cancer, 1997, 72(1), 133-141.
64. Helleman, J.; Jansen, M.P.H.M.; Burger, C.; van der Burg, M.E.L.; Berns, E.M.J.J. Integrated genomics of chemotherapy resistant ovarian cancer: A role for extracellular matrix, TGFbeta and regulating microRNAs. Int. J. Biochem Cell Biol., 2010, 42(1), 25-30.
65. Ahmed, A.A.; Mills, A.D.; Ibrahim, A.E.K.; Temple, J.; Blenkiron, C.; Vias, M.; Massie, C.E.; Gopalakrishna Iyer, N.; McGeoch, A.; Crawford, R.; Nicke, B.; Downward, J.; Swanton, C.; Bell, S.D.; Earl, H.M.; Laskey, R.A.; Caldas, C.; Brenton, J.D. The extracellular matrix protein TGFBI induces mictrotubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell, 2007, 12(6), 514-527.
66. Kurahara, H.; Shinchi, H.; Mataki, Y.; Maemura, K.; Noma, H.; Kubo, F.; Sakoda, M.; Ueno, S.; Natsugoe, S.; Takao, S. Signifi cance of M2-polarized tumor-associated macrophage in pancreatic cancer. J. Surg. Res., 2009, 167(2), e211-219.
67. Miyamoto, H.; Murakami, T.; Tsuchida, K.; Sugino, H.; Miyake, H.; Tashiro, S. Tumor-stroma interaction of human pancreatic cancer: Acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas, 2004, 28(1), 38-44.
68. Huanwen, W.; Zhiyong, L.; Xiaohua, S.; Xinyu, R.; Kai, W.; Tonghua, L. Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phsophorylation of FAK in pancreatic cancer cell lines. Mol. Cancer, 2009, 8, 125-140.
69. Furuyama, K.; Doi, R.; Mori, T.; Toyoda, E.; Ito, D.; Kami, K.; Koizumi, M.; Kida, A.; Kawaguchi, Y.; Fujimoto, K. Clinical significance of focal adhesion kinase in respectable pancreatic cancer. World J. Surg., 2006, 30(2), 219-226.
70. de Heer, P.; Koudijs, M.M.; van de Velde, C.J.; Aelbers, R.I.; Tollenaar, R.A.; Putter, H.; Morreau, J.; van de Water, B.; Kuppen, P.J. Combined expression of the non-receptor protein tyrosine kinases FAK and Src in primary colorectal cancer is associated with tumor recurrence and metastasis formation. Eur. J. Surg. Oncol., 2008, 34(11), 1253-1261.
71. Chatzizacharias, N.A.; Kouraklis, G.P.; Theocharis, S.E. Clinical significance of FAK expression in human neoplasia. Histol. Histopathol., 2008, 23(5), 629-650.
72. Halder, J.; Kamat, A.A.; Landen, C.N. Jr.; Han, L.Y.; Lutgendorf, S.K.; Lin, Y.G.; Merritt, W.M.; Jennings, N.B.; Chavez-Reyes, A.; Coleman, R.L.; Gershenson, D.M.; Schmandt, R.; Cole, S.W.; Lopez-Berestein, G.; Sood, A.K. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin. Cancer Res., 2006, 12(16), 4916-4924.
73. Duxbury, M.S.; Ito, H.; Benoit, E.; Zinner, M.J.; Ashley, S.W.; Whang, E.E. RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. Biochem. Biophys. Res. Commun., 2003, 311(3), 786-792.
74. Sebens Müerköster, S.; Werbing, V.; Koch, D.; Sipos, B.; Ammerpohl, O.; Kalthoff, H.; Tsao, M.-S.; Fölsch, U.R.; Schäfer, H. Role of myofibroblasts on innate chemoresistance in pancreatic carcinoma-epigenetic down-regulation of caspases. Int. J. Cancer, 2008, 123(8), 1751-1760.
75. Geismann, C.; Morscheck, M.; Koch, D.; Ungefroren, H.; Arlt, A.; Tsao, M.-S.; Bachem, M.G.; Altevogt, P.; Fölsch, U.R.; Schäfer, H.; Sebens Müerköster, S. The adhesion molecule L1CAM mediates myofibroblasts induced malignant transformation of pancreatic ductal epithelial cells by enhancing chemoresistance and migratory abilities. Cancer Res., 2009, 69(10), 4517-4526.
76. Arlt, A.; Vorndamm, J.; Müerköster, S.; Yu, H.; Schmidt, W.E.; Fölsch, U.R.; Schäfer, H. Autocrine production of Interleukin-1-beta confers constitutive NFeeB activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res., 2002, 62(3), 910-916.
77. Müerköster, S.; Arlt, A.; Witt, M.; Gehrz, A.; Haye, S.; March, C.; Grohmann, F.; Wegehenkel, K.; Kalthoff, H.; Fölsch, U.R.; Schäfer, H. Usage of the NF-B inhibitor Sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer. Int. J. Cancer, 2003, 104(4), 469-476.
78. Gavert, N.; Conacci-Sorrell, M.; Gast, D.; Schneider, A.; Altevogt, P.; Brabletz, T.; Ben-Zéev, A. L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J. Cell Biol., 2005, 168(4), 633-642.
79. Fogel, M.; Gutwein, P.; Mechtersheimer, S.; Riedle, S.; Stoeck, A.; Smirnov, A.; Edler, L.; Ben-Arie, A.; Huszar, M.; Altevogt, P. L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet, 2003, 362(9387), 869-875.
80. Izumoto, S.; Ohnishi, T.; Arita, N.; Hiraga, S.; Taki, T.; Hayakawa, T. Gene expression of neural cell adhesion molecule L1 in malignant gliomas and biological significance of L1 in glioma invasion. Cancer Res., 1996, 56(6), 1440-1444.
81. Raveh, S.; Gavert, N.; Ben-Zéev, A. L1 cell adhesion molecule (L1CAM) in invasive tumors. Cancer Lett., 2009, 282(2), 137-145.
82. Ben, Q.-W.; Wang, J.-C., Liu, J.; Zhu, Y.; Yuan, F.; Yao, W.-Y.; Yuan, Y.-Z. Positive expression of L1-CAM is associated with perineural invasion and poor outcome in pancreatic ductal adenocarcinoma. Ann. Surg. Oncol., 2010, 17(8), 2213-2221.
83. Sebens Müerköster, S.; Werbing, V.; Sipos, B.; Witt, M.; Großmann, M.; Leisner, D.; Kappes, H.; Klöppel, G.; Altevogt, P.; Fölsch, U.R.; Schäfer, H. Drug induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene, 2007, 26(19), 2759-2768.
84. Beer, S.; Oleszewski, M.; Gutwein, P.; Geiger, C.; Altevogt, P. Metalloproteinase-mediated release of the ectodomain of L1 adhesion molecule. J. Cell Sci., 1999, 112(pt16), 2667-2675.
85. Stoeck, A.; Schlich, S.; Issa, Y.; Geschwend, V.; Wenger, T.; Herr, I.; Marme, A.; Bourbie, S.; Altevogt, P.; Gutwein, P. L1 on ovarian carcinoma cells is a binding partner for Neuropilin-1 on mesothelial cells. Cancer Lett., 2005, 239(2), 212-226.
86. Sebens Müerköster, S.; Kötteritzsch, J.; Geismann, C.; Gast, D.; Kruse, M.-L.; Altevogt, P.; Fölsch, U.R.; Schäfer, H. 5-integrin is crucial for L1CAM-mediated chemoresistance in pancreatic adenocarcinoma. Int. J. Oncol., 2009, 34(1), 243-253.
87. Wey, J.S.; Gray, M.J.; Fan, F.; Belcheva, A.; McCarty, M.F.; Stoeltzing, O.; Somcio, R.; Liu, W.; Evans, D.B.; Klagsbrun, M.; Gallick, G.E.; Ellis, L.M. Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoreistance in pancreatic cancer cells. Brit. J. Cancer, 2005, 93(2), 233-241.
88. Choucair, A.K.; Levin, V.A.; Gutin, P.H.; Davis, R.L.; Silver, P.; Edwards, M.S.; Wilson, C.B. Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas. J. Neurosurg., 1986, 65(5), 654-658.
89. Gladson, C.L.; Cheresh, D.A. Glioblastoma expression of vitronectin and the avb3 integrin: adhesion mechanism for transformed glial cells. J. Clin. Invest., 1991, 88(6), 1924-1932.
90. Uhm, J.H.; Dolley, N.P.; Kyritsis, A.P.; Rao, J.S.; Gladson, C.L. Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death. Clin. Cancer Res., 1999, 5(6), 1587-1594.
91. Stromblad, S.; Becker, J.C.; Yebra, M.; Brooks, P.C.; Cheresh, D.A. Suppression of p53 activity and p21WAF/CIP1 expression by vascular cell integrin v 3 during angiogenesis. J. Clin. Invest., 1996, 98(2), 426-433.
92. Miyashita, T.; Krajeweski, S.; Krajewski, M.; Wang, H.G.; Lin, H.K.; Liebermann, D.A.; Hoffmann, B., Reed, J.C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene, 1994, 9(6), 1799-1805.
93. Westhoff, M.A.; Zhou, S.; Bachem, M.G.; Debatin, K.M.; Fulda, S. Identification of a novel switch in the domi39nant forms of cell adhesion-mediated drug resistance in glioblastoma cells. Oncogene, 2008, 27(39), 5169-5181.
94. Kouniavsky, G.; Khaikin, M.; Zvibel, I.; Zippel, D.; Brill, S.; Halpern, Z.; Papa, M. Stromal extracellular matrix reduces chemotherapy-induced apoptosis in colon cancer cell lines. Clin. Exp. Metastasis, 2002, 19(1), 55-60.
95. Kurose, K.; Gilley, S.; Matsumoto, P.H.; Watson, X.P.; Zhou, X.P.; Eng, C. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat. Genet., 2002, 32(3), 355-357.
96. Hill, R.; Song, Y.; Cardiff, R.D.; van Dyke, T. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell, 2005, 123(6), 1001-1011.
97. Bierie, B.; Moses, H.L. Under pressure: stromal fibroblasts change their ways. Cell, 2005, 123(6), 985-987.
98. Moinfar, F.; Man, Y.G., Arnould, L.; Bratthauer, G.L.; Ratschek, M.; Tavassoli, F.A. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. Cancer Res., 2000, 60(9), 2562-2566.
99. Komarova, E.A.; Diatchenko, L.; Rokhlin, O.W.; Hill, J.E.; Wang, Z.J.; Krivokrysenko, V.I.; Feinstein, E.; Gudkov, A.V. Stressinduced secretion of growth inhibitors: a novel tumor suppressor function of p53. Oncogene, 1998, 17(9), 1089-1096.
100. Lafkas, D.; Trimis, G.; Papavassaliliou, A.G.; Kiaris, H. p53 mutations in stromal fibroblasts sensitize tumors agains chemotherapy. Int. J. Cancer, 2008, 123(4), 967-971.
101. Lobo, N.A.; Shimono, Y.; Qian, D.; Clarke, M.F. The biology of cancer stem cells. Annu. Rev. Cell Dev. Biol., 2007, 23, 675-699.
102. Ailles, L.E.; Weissman, I.L. Cancer stem cells in solid tumors. Curr. Opin. Biotechnol., 2007, 18(5), 460-466.
103. Prince, M.E.; Sivanandan, R.; Kaczorowski, A.; Wolf, G.T.; Kaplan, M.J.; Dalerba, P.; Weissman, I.L.; Clarke, M.F.; Ailles, L.E. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc. Natl. Acad. Sci USA, 2007, 104(3), 973-978.
104. Dalerba, P.; Cho, R.W.; Clarke, M.F. Cancer stem cells: models and concepts. Annu. Rev. Med., 2007, 58, 267-284.
105. Hill, R. P; Perris, R. "Destemming" cancer stem cells. J. Natl. Cancer Inst., 2007, 99(19), 1435-1440.
106. Brabletz, T.; Jung, A.; Spaderna, S.; Hlubek, F.; Kirchner, T. Opinion: migrating cancer stem cells-an integrated concept of malignant tumour progression. Nat. Rev. Cancer, 2005, 5(9), 744-749.
107. Dean, M.; Fojo, T.; Bates, S. Tumour stem cells and drug resistance. Nat. Rev. Cancer, 2005, 5(4), 275-284.
108. Misra, S.; Ghatak, S.; Toole, B.P. Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J. Biol. Chem., 2005, 280(21), 20310-20315.
109. Toole, B.P. Hyaluronan: from extracellular glue to pericellular cue. Nat. Rev. Cancer, 2004, 4(7), 528-539.
110. Jenkins, R.H.; Thomas, G.J.; Williams, J.D., Steadman, R. Myofibroblastic differentiation leads to hyaluronan accumulation through reduced hyaluronan turnover. J. Biol. Chem., 2004, 279(40), 41453-41460.
111. Misra, S.; Ghatak, S.; Zoltan-Jones, A.; Toole, B.P. Regulation of multi-drug resistance in cancer cells by hyaluronan. J. Biol. Chem., 2003, 278(28), 25285-25288.
112. Bourguignon, L.Y.; Xia, W.; Wong, G. Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NFkappaB-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells. J. Biol. Chem., 2009, 284(5), 2657-2671.
113. Ohashi, R.; Takahashi, F.; Cui, R.; Yoshioka, M.; Gu, T.; Sasaki, S.; Tominaga, S.; Nishio, K.; Tanabe, K.K.; Takahashi, K. Interaction between CD44 and hyaluronate induces chemoresistance in nonsmall cell lung cancer cell. Cancer Lett., 2007, 252(2), 225-234.
114. Hong, S.P.; Wen, J.; Bang, S.; Park, S.; Song, S.Y. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int. J. Cancer, 2009, 125(10), 2323-2331.
115. Wang, S.J.; Bourguignon, L.Y. Hyaluronan and the interaction between CD44 and epidermal growth factor receptor in oncogenic signaling and chemotherapy resistance in head and neck cancer. Arch. Otolaryngol. Head Neck Surg., 2006, 132(7), 771-778.
116. Baumgartner, G.; Gomar-Hoss, C.; Sakr, L.; Ulsperger, E.; Wogritsch, C. The impact of extracellular matrix on the chemoresistance of solid tumors--experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy. Cancer Lett., 1998, 131(1), 85-99.
117. Gilg, A.G.; Tye, S.L.; Tolliver, L.B.; Wheeler, W.G.; Visconti, R.P.; Duncan, J.D.; Kostova, F.V.; Bolds, L, N.; Toole, B.P.; Maria, B.L. Targeting hyaluronan interactions in malignant gliomas and their drug-resistant multipotent progenitors. Clin. Cancer Res., 2008, 14(6), 1804-1813.
118. Burger, J.A.; Peled, A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia, 2009, 23(1), 43-52.
119. Burger, J.A.; Kipps, T.J. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood, 2006, 107(5), 1761-1767.
120. Gelmini, S.; Mangoni, M.; Serio, M.; Romagnani, P.; Lazzeri, E. The critical role of SDF-1/CXCR4 axis in cancer and cancer stem cells metastasis. J. Endocrinol. Invest., 2008, 31(9), 809-819.
121. Liu, G.; Yuan, X.; Zeng, Z.; Tunici, P.; Ng, H.; Abdulkadir, I.R.; Lu, L.; Irvin, D.; Black, K.L.; Yu, J.S. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer, 2006, 5, 67.
122. Hartmann, T.N.; Burger, J.A.; Glodek, A.; Fujii, N.; Burger, M. CXCR4 chemokine receptor and integrin signalling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene, 2005, 24(27), 4462-4471.
123. Stoeck, A.; Gast, D.; Sanderson M.P.; Issa, Y.; Gutwein, P.; Altevogt, P. L1-CAM in a membrane-bound or soluble form augments protection from apoptosis in ovarian carcinoma cells. Gynecol. Oncol., 2007, 104(2), 461-469.
124. Bao, S.; Wu, Q.; Sathornsumetee, S.; Wang, H.; McLendon, R.E.; Hjelmeland, A.B.; Rich, J.N. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res., 2008, 68(15), 6043-6048.
125. Olive, K.P.; Jacobetz, M.A.; Davidson, C.J.; Gopinathan, A.; McIntyre, D.; Honess, D.; Madhu, B.; Goldgraben, M.A.; Caldwell, M.E.; Allard, D.; Frese, K.K.; Denicola, G.; Feig, C.; Combs, C.; Winter, S.P.; Ireland-Zecchini, H.; Reichelt, S.; Howat, W.J.; Chang, A.; Dhara, M.; Wang, L.; Rückert, F.; Grützmann, R.; Pilarsky, C.; Izeradjene, K.; Hingorani, S.R.; Huang, P.; Davies, S.E.; Plunkett, W.; Egorin, M.; Hruban, R.H.; Whitebread, N.; McGovern, K.; Adams, J.; Iacobuzio-Donahue, C.; Griffiths, J.; Tuveson, D.A. Inhibition of Hedgehog Signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science, 2009, 324(5933), 1457-1461.
126. Delbaldo, C.; Raymond, E.; Vera, K.; Hammershaimb, L.; Kaucic, K.; Lozahic, S.; Marty, M.; Faivre, S. Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors. Invest. New Drugs, 2008, 26(1), 35-43.
127. Hersey, P.; Sosman, J.; O'Day, S.; Richards, J.; Bedikian, A.; Gonzalez, R.; Sharfman, W.; Weber, R.; Logan, T.; Buzoianu, M.; Hammershaimb, L.; Kirkwood, J.M. Etaracizumab Melanoma Study Group. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or-dacarbazine in patients with stage IV metastatic melanoma Cancer, 2010, 116(6), 1526-1534.
128. Mulgrew, K.; Kinneer, K.; Yao, X.T.; Ward, B.K.; Damschroder, M.M.; Walsh, B.; Mao, S.Y.; Gao, C.; Kiener, P.A.; Coats, S.; Kinch, M.S.; Tice, D.A. Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin. Mol. Cancer Ther., 2006, 5(12), 3122-3129.
129. Veeravagu, A.; Liu. Z.; Niu. G.; Chen, K.; Jia, B.; Cai, W.; Jin, C.; Hsu, A.R.; Connolly, A.J.; Tse, V.; Wang, F.; Chen, X. Integrin alphavbeta3-targeted radioimmunotherapy of glioblastoma multiforme. Clin, Cancer Res., 2008, 14(22), 7330-7339.
130. Burke, P.A.; DeNardo, S.J.; Miers, L.A.; Lamborn, K.R.; Matzku, S.; DeNardo, G.L. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res., 2002, 62(15), 4263-4272.
131. Reardon, D.A.; Fink, K.L.; Mikkelsen, T.; Cloughesy, T.F.; O'Neill, A.; Plotkin, S.; Glantz, M.; Ravin, P.; Raizer, J.J.; Rich, K.M.; Schiff, D.; Shapiro, W.R.; Burdette-Radoux, S.; Dropcho, E.J.; Wittemer, S.M.; Nippgen, J.; Picard, M.; Nabors, L.B. Randomized phase II study of cilengitide, an integrin-targeting argineglycine-aspartic acid peptide, in recurrent glioblastoma. J. Clin. Oncol., 2008, 26(34), 5610-5617.
132. Bradley, D.A.; Daignault, S.; Ryan, C.J.; Dipaola, R.S.; Smith, D.C.; Small, E.; Gross, M.E.; Stein, M.N.; Chen, A.; Hussain, M. Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Invest. New Drugs, 2010, [Epub ahead of print].
133. Desgrosellier, J.S.; Cheresh, D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer. 2010, 10(1), 9-22.
134. Mullamitha, S.A.; Ton, N.C.; Parker, G.J.; Jackson, A.; Julyan, P.J.; Roberts, C.; Buonaccorsi, G.A.; Watson, Y.; Davies, K.; Cheung, S.; Hope, L.; Valle, J.W.; Radford, J.A.; Lawrance, J.; Saunders, M.P.; Munteanu, M.C.; Nakada, M.T.; Nemeth, J.A.; Davis, H.M.; Jiao, Q.; Prabhakar, U.; Lang, Z.; Corringham, R.E.; Beckman, R.A.; Jayson, G.C. Phase I evaluation of a fully human antialphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin. Cancer Res., 2007, 13(7), 2128-2135.
135. Ning, S.; Nemeth, J.A.; Hanson, R.L.; Forsythe, K.; Knox, S.J. Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo. Mol. Cancer Ther., 2008, 7(6), 1569-1578.
136. Cianfrocca, M.E.; Kimmel, K.A.; Gallo, J.; Cardoso, T.; Brown, M.M.; Hudes, G.; Lewis, N.; Weiner, L.; Lam, G.N.; Brown, S.C.; Shaw, D.E.; Mazar, A.P.; Cohen, R.B. Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2), a beta integrin antagonist, in patients with solid tumours. Br. J. Cancer, 2006, 94(11), 1621-1926.
137. Stoeltzing, O.; Liu, W.; Reinmuth, N.; Fan, F.; Parry, G.C.; Parikh, A.A.; McCarty, M.F.; Bucana, C.D.; Mazar, A.P.; Ellis, L.M. Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int. J. Cancer, 2003, 104(4), 496-503.
138. Doñate, F.; Parry, G.C.; Shaked, Y.; Hensley, H.; Guan, X.; Beck, I.; Tel-Tsur, Z.; Plunkett, M.L.; Manuia, M.; Shaw, D.E.; Kerbel, R.S.; Mazar, A.P. Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2): observation of a U-shaped doseresponse curve in several preclinical models of angiogenesis and tumor growth. Clin. Cancer Res., 2008, 14(7), 2137-2144.
139. Keizer, R.J.; Zamacona, M.K.; Jansen, M.; Critchley, D.; Wanders, J.; Beijnen, J.H.; Schellens, J.H.; Huitema, A.D. Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820. Invest. New Drugs, 2009, 27(2), 140-152.
140. Funahashi, Y.; Sugi, N.H.; Semba, T.; Yamamoto, Y.; Hamaoka, S.; Tsukahara-Tamai, N.; Ozawa, Y.; Tsuruoka, A.; Nara, K.; Takahashi, K.; Okabe, T.; Kamata, J.; Owa, T.; Ueda, N.; Haneda, T.; Yonaga, M.; Yoshimatsu, K.; Wakabayashi, T. Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. Cancer Res., 2002, 62(21), 6116-6123.
141. Ricart, A.D.; Tolcher, A.W.; Liu, G.; Holen, K.; Schwartz, G.; Albertini, M.; Weiss, G.; Yazji, S.; Ng, C.; Wilding, G. Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study. Clin. Cancer Res., 2008, 14(23), 7924-7929.
142. Bhaskar, V.; Fox, M.; Breinberg, D.; Wong, M.H.; Wales, P.E.; Rhodes, S.; DuBridge, R.B.; Ramakrishnan, V. A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo. Invest. New Drugs, 2008, 26(1), 7-12.
143. Arlt, M.J.; Novak-Hofer, I.; Gast, D.; Gschwend, V.; Moldenhauer, G.; Grünberg, J.; Honer, M.; Schubiger, P.A.; Altevogt, P.; Krüger, A. Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment. Cancer Res., 2006, 66(2), 936-943.
144. Bartolazzi, A.; Peach, R.; Aruffo, A.; Stamenkovic, I. Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. J. Exp. Med., 1994, 180(1), 53-66
145. Yu, Q.; Toole, B.P. Stamenkovic, I. Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. J. Exp. Med., 1997, 186(12), 1985-1996.
146. Peterson, R.M.; Yu, Q.; Stamenkovic, I.; Toole, B.P. Perturbation of hyaluronan interactions by soluble CD44 inhibits growth of murine mammary carcinoma cells in ascites. Am. J. Pathol., 2000, 156(6), 2159-2167.
147. Ahrens, T.; Sleeman, J.P.; Schempp, C.M.; Howells, N.; Hofmann, M.; Ponta, H.; Herrlich, P.; Simon, J.C. Soluble CD44 inhibits melanoma tumor growth by blocking cell surface CD44 binding to hyaluronic acid. Oncogene, 2001, 20(26), 3399-4308.
148. Guo, Y.; Ma, J.; Wang, J.; Che, X.; Narula, J.; Bigby, M.; Wu, M.; Sy, M.S. Inhibition of human melanoma growth and metastasis in vivo by anti-CD44 monoclonal antibody. Cancer Res., 1994, 54(6), 1561-1565.
149. Zahalka, M.A.; Okon, E.; Gosslar, U.; Holzmann, B.; Naor, D. Lymph node (but not spleen) invasion by murine lymphoma is both CD44-and hyaluronate-dependent. J. Immunol., 1995, 154(10), 5345-5355.
150. Mohapatra, S.; Yang, X.; Wright, J.A.; Turley, E.A.; Greenberg, A.H. Soluble hyaluronan receptor RHAMM induces mitotic arrest by suppressing Cdc2 and cyclin B1 expression. J. Exp. Med., 1996, 183(4),1663-1668.
151. Liu, N.; Lapcevich, R.K.; Underhill, C.B.; Han, Z.; Gao, F.; Swartz, G.; Plum, S.M.; Zhang, L.; Gree, S.J. Metastatin: a hyaluronan-binding complex from cartilage that inhibits tumor growth. Cancer Res., 2001, 61(3), 1022-1028.
152. Zeng, C.; Toole, B.P.; Kinney, S.D.; Kuo, J.W.; Stamenkovic, I. Inhibition of tumor growth in vivo by hyaluronan oligomers. Int. J. Cancer, 1998, 77(3), 396-401.
153. Ghatak, S.; Misra, S.; Toole, BP. Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J. Biol. Chem., 2002, 277(41), 38013-38020.
154. Ghatak, S.; Misra, S.; Toole, B.P. Hyaluronan constitutively regulates ErbB2 phosphorylation and signal complex formation in carcinoma cells. J. Biol. Chem., 2005, 280(21), 8875-8883.
155. Misra, S.; Toole, B.P.; Ghatak, S. Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells. J. Biol. Chem., 2006, 281(46), 34936-34941.
156. Misra, S.; Hascall, V.C.; De Giovanni, C.; Markwald, R.R.; Ghatak, S. Delivery of CD44 shRNA/nanoparticles within cancer cells: perturbation of hyaluronan/CD44v6 interactions and reduction in adenoma growth in Apc Min/+ MICE. J. Biol. Chem., 2009, 284(18), 12432-12446.
157. Khakoo, A.Y.; Pati, S.; Anderson, S.A.; Reid, W.; Elshal, M.F.; Rovira; I.I.; Nguyen, A.T.; Malide, D.; Combs, C.A.; Hall, G.; Zhang, J.; Raffeld, M.; Rogers, T.B.; Stetler-Stevenson, W.; Frank, J.A.; Reitz, M.; Finkel, T. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Karposís sarcoma. J. Exp. Med., 2006, 203(5), 1235-1247.
158. Nakashima, H.; Masuda, M.; Murakami, T.; Koyanagi, Y.; Matsumoto, A.; Fujii, N.; Yamamoto, N. Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusion. Antimicrob. Agents Chemother., 1992, 36(6), 1249-1255.
159. Smith, M.C.; Luker, K.E.; Garbow, J.R.; Prior, J.L.; Jackson, E.; Piwnica-Worms, D.; Luker, G.D. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res., 2004, 64(23), 8604-8612.
160. Ottaiano, A.; Franco, R.; Aiello Talamanca, A.; Liguori, G.; Tatangelo, F.; Delrio, P.; Nasti, G.; Barletta, E.; Facchini, G.; Daniele, B.; Di Blasi, A.; Napolitano, M.; Ieranò, C.; Calemma, R.; Leonardi, E.; Albino, V.; De Angelis, V.; Falanga, M.; Boccia, V.; Capuozzo, M.; Parisi, V.; Botti, G.; Castello, G.; Vincenzo Iaffaioli, R.; Scala, S. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clin. Cancer Res., 2006, 12(9), 2795-2803.
161. Allen, C.D.; Ansel, K.M.; Low, C.; Lesley, R.; Tamamura, H.; Fujii, N.; Cyster, J.G. Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat. Immunol., 2004, 5(9), 943-952.
162. Ara, T.; Itoi, M.; Kawabata, K.; Egawa, T.; Tokoyoda, K.; Sugiyama, T.; Fujii, N.; Amagai, T.; Nagasawa, T. A role of CXC chemokine ligand 12/stromal cell-derived factor-1/pre-B cell growth stimulating factor and its receptor CXCR4 in fetal and adult T cell development in vivo. J. Immunol., 2003, 170(9), 4649-4655.
163. Turzanski, J.; Grundy, M.; Russell, N.H.; Pallis, M. Interleukin-1beta maintains an apoptosis-resistant phenotype in the blast cells of acute myeloid leukaemia via multiple pathways. Leukemia, 2004, 18(10), 1662-1670.
164. Angst, E.; Reber, H.A.; Hines, O.J.; Eibl, G. Mononuclear cellderived interleukin-1 beta confers chemoresistance in pancreatic cancer cells by upregulation of cyclooxygenase-2. Surgery, 2008, 144(1), 57-65.
165. Dinarello, CA. Why not treat human cancer with interleukin-1 blockade? Cancer Metast. Rev., 2010, 29, 317-329.
166. Lust, J. A.; Lacy, M. Q.; Zeldenrust, S. R.; Dispenzieri, A.; Gertz, M. A.; Witzig, T. E.; Kumar, S.; Hayman, S.R.; Russell, S.J.; Buadi, F.K.; Geyer, S.M.; Campbell, M.E.; Kyle, R.A.; Rajkumar, S.V.; Greipp; P.R.; Kline, M.P.; Xiong, Y.; Moon-Tasson, L.L.; Donovan, K.A. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin. Proc., 2009, 84(2), 114-122.
167. McMillin, D.W.; Delmore, J.; Weisberg, E.; Negri, J.M.; Geer, D.C., Klippel, S.; Mitsiades, N.; Schlossman, R.L.; Munshi, N.C.; Kung, A.L.; Griffin, J.D.; Richardson, P.G.; Anderson, K.C.; Mitsiades, C.S. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat. Med., 2010, 16(4), 483-489.